Are you Dr. Yang?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 43 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
12605 E 16th Ave
Aurora, CO 80045Phone+1 720-777-1234
Summary
- Dr. Michael Yang, MD is a board certified pathologist in Aurora, Colorado. He is currently licensed to practice medicine in Colorado, Ohio, and New York. He is affiliated with University of Colorado Hospital and is an Assistant Professor at Case Western Reserve University School of Medicine.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Cytopathology, 2009 - 2010
- New York Presbyterian Hospital (Cornell Campus)Residency, Anesthesiology, 2006 - 2009
- University of California (San Francisco)/FresnoInternship, Internal Medicine, 2005 - 2006
- University of California San Francisco School of MedicineClass of 2004
Certifications & Licensure
- CO State Medical License 2019 - 2025
- OH State Medical License 2009 - 2021
- CA State Medical License Active through 2014
- NY State Medical License 2006 - 2010
- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Cytopathology
Publications & Presentations
PubMed
- 9 citationsA prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancerXiangxue Wang, Kaustav Bera, Cristian Barrera, Yu Zhou, Cheng Lu
Ebiomedicine. 2021-07-01 - 136 citationsSpatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer.Germán Corredor, Xiangxue Wang, Yu Zhou, Cheng Lu, Pingfu Fu
Clinical Cancer Research. 2019-03-01 - 30 citationsSpatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors.Xiangxue Wang, Cristian Barrera, Kaustav Bera, Vidya Sankar Viswanathan, Sepideh Azarianpour-Esfahani
Science Advances. 2022-06-03